Orlance Teams Up With Product Creation Studio To Enhance MACH-1 Vaccine System

Orlance, a Seattle-based biotech company, has announced a new development project with Product Creation Studio (PCS), a leader in engineering and design services. This collaboration aims to advance the MACH-1 system, preparing it for Phase 1 clinical trials. The MACH-1 system is designed for needle-free delivery of powdered DNA and RNA vaccines and therapeutics.

The MACH-1 system is expected to significantly impact the fight against influenza, other potential pandemics, and immunotherapy treatment shortcomings. PCS will leverage its expertise in product development to help Orlance achieve critical milestones. Engineers and designers at PCS will focus on optimizing the MACH-1 system's design, facilitating its progression through clinical trial phases.

PCS provides on-demand collaboration in physical product design, prototyping capabilities, and medtech knowledge. This partnership allows Orlance to concentrate on scientific achievements while PCS handles device development intricacies. Kristyn Aalto, CEO of Orlance Inc., commented on the collaboration.

"Accessing Product Creation Studio’s expertise allows us to focus on our scientific objectives without the overhead of maintaining a large in-house team. This strategic approach accelerates our path to clinical trials and ultimately to market," said Aalto.

Scott Thielman, CTO of Product Creation Studio, added, "The Orlance team members are true innovators in their field, and we are proud to support them in pioneering a new formulation and delivery mode for vaccines and immunotherapies. Our ongoing partnership exemplifies how strategic collaboration can enhance technological advancements and deliver real health solutions."

Located in Seattle, Washington, Product Creation Studio (PCS) has served as an innovation accelerator since 1999. The company transforms ideas into market-ready products with expertise spanning medical devices, life science tools, industrial equipment, and consumer products. PCS focuses on enhancing user experience and expediting time to market.

For more information on Product Creation Studio: https://www.productcreationstudio.com/.

About Orlance Inc.

Orlance Inc., a biotech leader based in Seattle, Washington, is dedicated to advancing low-dose, needle-free vaccines and therapeutics. Founded as a University of Washington spinout in 2016, Orlance has been at the forefront of developing the MACH-1 system. This novel technology aims to enable greater utility and reduced complications associated with DNA and RNA vaccines and therapies.

MACH-1 shelf-stable vaccines have significant potential impact on global vaccine distribution. For more information on Orlance Inc.: https://orlance.com/.

Disclaimer: The U.S. Food and Drug Administration has not yet approved this device.